Evidence map›Paper›PMID 26407555›Full record

ArticleJournal of the American Society for Mass Spectrometry2016

Identification of Biomarkers of Necrosis in Xenografts Using Imaging Mass Spectrometry.

Roberto Fernández, Jone Garate, Sergio Lage, Silvia Terés, Mónica Higuera, Joan Bestard-Escalas, Daniel H López, Francisca Guardiola-Serrano, Pablo V Escribá, Gwendolyn Barceló-Coblijn and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Roberto FernándezDepartment of Physical Chemistry, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Barrio Sarriena s/n, Bilbao, 48940, Spain.
Jone GarateDepartment of Physical Chemistry, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Barrio Sarriena s/n, Bilbao, 48940, Spain.
Sergio LageDepartment of Physical Chemistry, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Barrio Sarriena s/n, Bilbao, 48940, Spain.
Silvia TerésUnité de recherche Inserm 0916, Institut européen de chimie et biologie (IECB)-INSERM, 2, rue Robert Escarpit, 33607, Pessac, France.
Mónica HigueraLaboratory of Molecular and Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122, Palma, Balearic Islands, Spain.
Joan Bestard-EscalasResearch Unit, Hospital Universitari Son Espases, Institut d'Investigació Sanitària de Palma (IdISPa), Ctra. Valldemossa 79, E-07010, Palma, Balearic Islands, Spain.
Daniel H LópezResearch Unit, Hospital Universitari Son Espases, Institut d'Investigació Sanitària de Palma (IdISPa), Ctra. Valldemossa 79, E-07010, Palma, Balearic Islands, Spain.
Francisca Guardiola-SerranoLaboratory of Molecular and Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122, Palma, Balearic Islands, Spain.
Pablo V EscribáLaboratory of Molecular and Cell Biomedicine, Department of Biology, University of the Balearic Islands, 07122, Palma, Balearic Islands, Spain.
Gwendolyn Barceló-CoblijnResearch Unit, Hospital Universitari Son Espases, Institut d'Investigació Sanitària de Palma (IdISPa), Ctra. Valldemossa 79, E-07010, Palma, Balearic Islands, Spain. gwendolyn.barcelo@ssib.es.
José A FernándezDepartment of Physical Chemistry, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Barrio Sarriena s/n, Bilbao, 48940, Spain. josea.fernandez@ehu.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xenografts are commonly used to test the effect of new drugs on human cancer. However, because of their heterogeneity, analysis of the results is often controversial. Part of the problem originates in the existence of tumor cells at different metabolic stages: from metastatic to necrotic cells, as it happens in real tumors. Imaging mass spectrometry is an excellent solution for the analysis of the results as it yields detailed information not only on the composition of the tissue but also on the distribution of the biomolecules within the tissue. Here, we use imaging mass spectrometry to determine the distribution of phosphatidylcholine (PC), phosphatidylethanolamine (PE), and their plasmanyl- and plasmenylether derivatives (PC-P/O and PE-P/O) in xenografts of five different tumor cell lines: A-549, NCI-H1975, BX-PC3, HT29, and U-87 MG. The results demonstrate that the necrotic areas showed a higher abundance of Na(+) adducts and of PC-P/O species, whereas a large abundance of PE-P/O species was found in all the xenografts. Thus, the PC/PC-ether and Na(+)/K(+) ratios may highlight the necrotic areas while an increase on the number of PE-ether species may be pointing to the existence of viable tumor tissues. Furthermore, the existence of important changes in the concentration of Na(+) and K(+) adducts between different tissues has to be taken into account while interpreting the imaging mass spectrometry results. Graphical Abstract ᅟ.

Indexed as

AnimalsBiomarkersCell Line, TumorChromatography, High Pressure LiquidHeterograftsHumansLipidsMaleMass SpectrometryMice, NudeNecrosisPhosphatidylcholinesPhosphatidylethanolaminesPlasmalogensPotassiumSodiumBiomarkersLipidsPhosphatidylcholinesphosphatidylethanolaminePhosphatidylethanolaminesPlasmalogensPotassiumSodiumBiomarkersEther lipidsImaging mass spectrometryLipidomicsXenografts

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.